Skip to Content

GV16-01a

Main Content

Graft-versus-host disease-free relapse-free survival in alternative donor hematopoietic cell transplantation.

Study #: GV16-01a

Study Status: Published

Presentation(s)

2017, ASH (Oral)

Composite GRFS and CRFS outcomes after adult alternative donor HCT.

Citation

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, Ahmed I, Al-Homsi AS, Aljurf M, Antin JH, Askar M, Auletta JJ, Bhatt VR, Chee L, Chhabra S, Daly A, DeFilipp Z, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Hogan WJ, Inamoto Y, Martino R, Majhail NS, Marks DI, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Rangarajan HG, Ringden O, Saad A, Savani BN, Schoemans H, Seo S, Schultz KR, Solh M, Spitzer T, Storek J, Teshima T, Verdonck LF, Wirk B, Yared JA, Cahn J-Y, Weisdorf DJ.

Journal of Clinical Oncology. 2020, Jun 20: 38(18): 38(18):2062-2076. doi: 10.1200/JCO.19.00396. Epub 2020, May 04. PMCID:PMC7302955.

PubMed

PMID: 32364845

Abstract